Figure 7From: Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis Acceptability curve (incremental cost/LYG). Lifetime decision model (high risk patients with APACHE II = 25, 3% discounting, 20-year time horizon). LYG = life-years gained.Back to article page